Dr. Martin Mintchev, primary developer of the innovative medical technologies held by M Pharmaceutical Inc. (CSE:MQ), has been appointed President & Chief Executive Officer of the company.
As quoted in the press release:
Dr. Mintchev is the primary developer of the innovative medical technologies held by M Pharmaceutical. The company is focused on two groups of medical devices developed to enhance the quality of life of people living with diabetes and/or obesity, including the eMosquito currently held by M Pharmaceutical and the pseudobezoar technologies acquired through the purchase of RX Global Capital Inc.
A veteran academic in the field, Dr. Mintchev will continue his role as a Professor in the Schulich School of Engineering at the University of Calgary, but will be able to devote the leadership required in order to move forward the development of the Company’s medical devices.
“This company represents an opportunity to apply the expertise I have gained over decades in order to deliver realistic solutions that reduce invasiveness and enhance effectiveness for millions of people who require more options when facing obesity and diabetes,” said Dr. Mintchev, a native of Bulgaria who holds the designations of PhD and PEng.
The Board of Directors of M Pharmaceutical, Inc. wishes to thank David Lane for his work and service to the company as its former president and director.